Alice Talbot1,2, Emily O'Donovan3, Eileen Berkley3, Carmel Nolan3, Roisin Clarke3, David Gallagher3,4. 1. The Royal College of Surgeons of Ireland (RCSI), Dublin, Ireland. alicetalbot@rcsi.ie. 2. Department of Cancer Genetics, St. James' Hospital, James' Street, Dublin, Ireland. alicetalbot@rcsi.ie. 3. Department of Cancer Genetics, St. James' Hospital, James' Street, Dublin, Ireland. 4. Mater Private Hospital, Eccles Street, Dublin, Ireland.
Abstract
BACKGROUND: Lynch syndrome (LS) is an autosomal dominant hereditary cancer syndrome responsible for 2-4% of hereditary colorectal cancers (CRC). Mismatch repair protein deficiency (dMMR) is a characteristic feature of LS. It has been associated with a poor response to standard chemotherapy in metastatic colorectal cancer (mCRC). There is currently no LS database to monitor trends of disease in Ireland. We aim to centralise LS data in Ireland to assess the burden of LS in Ireland and guide improvements in prevention and treatment of LS-associated cancer. METHODS: A retrospective review was carried out including all medical records for LS patients from two of the three cancer genetics clinics in Ireland between 2000 and 2018 was carried out. Clinicopathological data of probands (n = 57) and affected family members including demographics, mutation status, cancer diagnosis and outcome was recorded. Statistical analysis was carried out using SPSS software. RESULTS: Fifty-seven families including three-hundred and forty-five individuals affected by cancer were identified. The most common cancers recorded were colorectal (53%), breast (12%) and endometrial (10%). One-hundred and thirty-eight confirmed carriers were identified: 65 path_MLH1 (47%), 43 path_MSH2 (31%), 11 path_MSH6 (8%), 17 path_PMS2 (12%) and two path_EPCAM (1%). Cancer type varied significantly by gene. Median age of first diagnosis was 44.5 years (range 23-81). Half of all deceased patients (n = 11) in this group died within 2.5 years of first diagnosis. These deaths were directly related to cancer in 59% of cases. CONCLUSIONS: Under diagnosis of LS misses a powerful preventive and therapeutic opportunity. LS causes early onset dMMR cancer diagnoses with substantial societal impact. Implementation of ICBs into treatment policy for this small cohort of dMMR mCRC is an achievable therapeutic goal that may significantly improve survival. A prospective database for LS in Ireland is necessary to maximise prevention in this population.
BACKGROUND:Lynch syndrome (LS) is an autosomal dominant hereditary cancer syndrome responsible for 2-4% of hereditary colorectal cancers (CRC). Mismatch repair protein deficiency (dMMR) is a characteristic feature of LS. It has been associated with a poor response to standard chemotherapy in metastatic colorectal cancer (mCRC). There is currently no LS database to monitor trends of disease in Ireland. We aim to centralise LS data in Ireland to assess the burden of LS in Ireland and guide improvements in prevention and treatment of LS-associated cancer. METHODS: A retrospective review was carried out including all medical records for LS patients from two of the three cancer genetics clinics in Ireland between 2000 and 2018 was carried out. Clinicopathological data of probands (n = 57) and affected family members including demographics, mutation status, cancer diagnosis and outcome was recorded. Statistical analysis was carried out using SPSS software. RESULTS: Fifty-seven families including three-hundred and forty-five individuals affected by cancer were identified. The most common cancers recorded were colorectal (53%), breast (12%) and endometrial (10%). One-hundred and thirty-eight confirmed carriers were identified: 65 path_MLH1 (47%), 43 path_MSH2 (31%), 11 path_MSH6 (8%), 17 path_PMS2 (12%) and two path_EPCAM (1%). Cancer type varied significantly by gene. Median age of first diagnosis was 44.5 years (range 23-81). Half of all deceased patients (n = 11) in this group died within 2.5 years of first diagnosis. These deaths were directly related to cancer in 59% of cases. CONCLUSIONS: Under diagnosis of LS misses a powerful preventive and therapeutic opportunity. LS causes early onset dMMR cancer diagnoses with substantial societal impact. Implementation of ICBs into treatment policy for this small cohort of dMMR mCRC is an achievable therapeutic goal that may significantly improve survival. A prospective database for LS in Ireland is necessary to maximise prevention in this population.
Authors: Thierry André; Kai-Keen Shiu; Tae Won Kim; Benny Vittrup Jensen; Lars Henrik Jensen; Cornelis Punt; Denis Smith; Rocio Garcia-Carbonero; Manuel Benavides; Peter Gibbs; Christelle de la Fouchardiere; Fernando Rivera; Elena Elez; Johanna Bendell; Dung T Le; Takayuki Yoshino; Eric Van Cutsem; Ping Yang; Mohammed Z H Farooqui; Patricia Marinello; Luis A Diaz Journal: N Engl J Med Date: 2020-12-03 Impact factor: 91.245
Authors: Alexandra Khichfy Alex; Sheila Siqueira; Renata Coudry; Juliana Santos; Michel Alves; Paulo M Hoff; Rachel P Riechelmann Journal: Clin Colorectal Cancer Date: 2016-11-26 Impact factor: 4.481
Authors: Christoph Engel; Hans F Vasen; Toni Seppälä; Stefan Aretz; Marloes Bigirwamungu-Bargeman; Sybrand Y de Boer; Karolin Bucksch; Reinhard Büttner; Elke Holinski-Feder; Stefanie Holzapfel; Robert Hüneburg; Maarten A J M Jacobs; Heikki Järvinen; Matthias Kloor; Magnus von Knebel Doeberitz; Jan J Koornstra; Mariette van Kouwen; Alexandra M Langers; Paul C van de Meeberg; Monika Morak; Gabriela Möslein; Fokko M Nagengast; Kirsi Pylvänäinen; Nils Rahner; Laura Renkonen-Sinisalo; Silvia Sanduleanu; Hans K Schackert; Wolff Schmiegel; Karsten Schulmann; Verena Steinke-Lange; Christian P Strassburg; Juda Vecht; Marie-Louise Verhulst; Wouter de Vos Tot Nederveen Cappel; Silke Zachariae; Jukka-Pekka Mecklin; Markus Loeffler Journal: Gastroenterology Date: 2018-07-29 Impact factor: 22.682
Authors: Michael J Overman; Sara Lonardi; Ka Yeung Mark Wong; Heinz-Josef Lenz; Fabio Gelsomino; Massimo Aglietta; Michael A Morse; Eric Van Cutsem; Ray McDermott; Andrew Hill; Michael B Sawyer; Alain Hendlisz; Bart Neyns; Magali Svrcek; Rebecca A Moss; Jean-Marie Ledeine; Z Alexander Cao; Shital Kamble; Scott Kopetz; Thierry André Journal: J Clin Oncol Date: 2018-01-20 Impact factor: 44.544
Authors: Daniel J Sargent; Silvia Marsoni; Genevieve Monges; Stephen N Thibodeau; Roberto Labianca; Stanley R Hamilton; Amy J French; Brian Kabat; Nathan R Foster; Valter Torri; Christine Ribic; Axel Grothey; Malcolm Moore; Alberto Zaniboni; Jean-Francois Seitz; Frank Sinicrope; Steven Gallinger Journal: J Clin Oncol Date: 2010-05-24 Impact factor: 44.544
Authors: Kevin J Monahan; Nicola Bradshaw; Sunil Dolwani; Bianca Desouza; Malcolm G Dunlop; James E East; Mohammad Ilyas; Asha Kaur; Fiona Lalloo; Andrew Latchford; Matthew D Rutter; Ian Tomlinson; Huw J W Thomas; James Hill Journal: Gut Date: 2019-11-28 Impact factor: 23.059
Authors: Pål Møller; Toni T Seppälä; Inge Bernstein; Elke Holinski-Feder; Paulo Sala; D Gareth Evans; Annika Lindblom; Finlay Macrae; Ignacio Blanco; Rolf H Sijmons; Jacqueline Jeffries; Hans F A Vasen; John Burn; Sigve Nakken; Eivind Hovig; Einar Andreas Rødland; Kukatharmini Tharmaratnam; Wouter H de Vos Tot Nederveen Cappel; James Hill; Juul T Wijnen; Mark A Jenkins; Kate Green; Fiona Lalloo; Lone Sunde; Miriam Mints; Lucio Bertario; Marta Pineda; Matilde Navarro; Monika Morak; Laura Renkonen-Sinisalo; Mev Dominguez Valentin; Ian M Frayling; John-Paul Plazzer; Kirsi Pylvanainen; Maurizio Genuardi; Jukka-Pekka Mecklin; Gabriela Moeslein; Julian R Sampson; Gabriel Capella Journal: Gut Date: 2017-07-28 Impact factor: 23.059